drugset
drugset / Trial / NCT00446303

A Phase II Study of Maintenance With Azacitidine in MDS Patients

NCT00446303 ↗

Phase 2 Terminated 39 enrolled Groupe Francophone des Myelodysplasies Celgene Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A phase II multicentre trial of maintenance with Azacitidine in MDS patients achieving complete or partial remission (CR or PR) after intensive chemoterapy. The primary objective is response duration (MDS or AML)

Timeline

Start
2006-07
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 60 mg/m2 —

Indications

acute myeloid leukemia myelodysplastic syndrome